Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

NACompletedINTERVENTIONAL
Enrollment

1,939

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Melanoma
Interventions
PROCEDURE

Completion Lymphadenectomy

complete lymph node dissection of lymph node basin with positive node

PROCEDURE

Monitoring with nodal ultrasound

serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.

Trial Locations (63)

2060

Melanoma Institute Australia, Sydney

2298

Newcastle Melanoma Unit, Newcastle

3123

Alfred Hospital, East Hawthorn

3677

Peter MacCallum Cancer Centre, East Melbourne

4102

Princess Alexandra Hospital, Woolloongabba

10065

Memorial Sloan-Kettering Cancer Center, New York

11021

Feinstein Institute for Medical Research, Great Neck

14209

Buffalo General Hospital, Buffalo

17033

Pennsylvania State Hershey Cancer Institute, Hershey

17822

Geisinger Clinic, Danville

18015

St. Luke's Hospital, Bethlehem

19096

Main Line Surgeons, Wynnewood

19107

Thomas Jefferson University, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

20141

Istituto Europeo di Oncologia, Milan

21202

Mercy Medical Center, Baltimore

21287

Johns Hopkins Medical Institute, Baltimore

22908

University of Virginia, Charlottesville

23538

U. Hosp. Schleswig-Holstein/Campus Lubeck, Lübeck

23606

Sentara Careplex Hospital, Newport News

27157

Wake Forest University, Winston-Salem

27710

Duke University Medical Center, Durham

29605

Greenville Hospital System Cancer Center, Greenville

33805

Lakeland Regional Cancer Center, Lakeland

35128

Istituto Oncologico Veneto - University of Padova, Padua

Padua University - Clinica Chirurgica II, Padua

37920

University of Tennessee Medical Center, Knoxville

40202

University of Louisville, Louisville

43210

Ohio State University, Columbus

45219

University of Cincinnati, Cincinnati

53792

University of Wisconsin, Madison

60611

Northwestern University Feinberg School of Medicine, Chicago

75235

Dallas Surgical Group, Dallas

77030

MD Anderson Cancer Center, Houston

80121

Istituto Nazionale dei Tumori Napoli, Naples

84103

IHC Cancer Services Intermountain Medical Center, Salt Lake City

84112

Hunstman Cancer Institute, Salt Lake City

90404

John Wayne Cancer Institute, Santa Monica

90419

City Hospital of Nurnberg, Nuremberg

92123

Sharp Hospital, San Diego

94239

Tel-Aviv Sourasky Medical Center, Tel Aviv

97080

University of Wurzburg, Würzburg

98195

University of Washington, Seattle

809030-3658

Memorial Hospital - Colorado Springs, Colorado Springs

33612-9497

H. Lee Moffitt Cancer Center, Tampa

60612-3824

Rush University, Chicago

48109-0932

University of Michigan, Ann Arbor

63110-8566

St. Louis University, St Louis

03756

Dartmouth-Hitchcock Medical Center, Lebanon

14263-0001

Roswell Park Cancer Institute, Buffalo

11794-8191

SUNY at Stony Brook Hospital Medical Center, Stony Brook

37232-6868

Vanderbilt University, Nashville

T2N 4N1

Tom Baker Cancer Center, Calgary

M4N3M5

Sunnybrook Health Sciences Center, Toronto

00029 HUS

Helsinki Unversity Hospital, Helsinki

1066 CX

Netherlands Cancer Institute, Amsterdam

9700 RB

Universitair Medisch Centrum Groningen, Groningen

08036

Hospital Clinic Barcelona, Barcelona

S-221 85

Swedish Melanoma Study Group, Lund

CH 1011

Centre Hospitalier Universitaire Vaudois, Lausanne

CH-8091

University of Zurich, Zurich

NR4 7UY

Norfolk and Norwich University Hospital, Norfolk

SE17EH

Saint Thomas's Hospital, London

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Saint John's Cancer Institute

OTHER

NCT00297895 - Multicenter Selective Lymphadenectomy Trial II (MSLT-II) | Biotech Hunter | Biotech Hunter